Development of a proton pump inhibitor protocol in the prophylaxis of acute gastric mucosal injury: experience report

Authors

DOI:

https://doi.org/10.33448/rsd-v11i8.30865

Keywords:

Antiulcers; Proton pump inhibitors; Treatment protocol; Acute gastric mucosal injury.

Abstract

The present work aims to describe the elaboration of a protocol for the use of proton pump inhibitors in the prophylaxis of acute gastric mucosal injury (LAMG). This is a cross-sectional and descriptive study, of the experience report type, which was developed from June to October 2021. The protocol was elaborated based on the model proposed by Stetler (1998) which consists of the following phases: 1) establishment of the purposes of the literature review; 2) critical analysis of studies; 3) data collection; 4) protocol construction. A bibliographic review was carried out in Pubmed, Virtual Health Library (BVS), UpToDate, and Scielo databases. The chronic use of proton pump inhibitors, not supported by clinical evidence, is still remarkable in the national and world scenario. In this sense, institutional protocols emerge as an alternative that aims to reinforce the safety and efficacy of clinical care, rationalize and standardize prescriptions and, consequently, reduce costs.

Author Biographies

Damaris Santana Cardoso, Federal University of Sergipe

Pharmacist from the Federal University of Sergipe (2016). Specialist in quality of magistral pharmacy and Clinical Pharmacy and Pharmaceutical Care. Has experience in the field of Masterful Pharmacy.
Currently resident in Hospital Health Care (HUL - UFS) and collaborate in a Drug Information Center (CIM-UFS).

Luiz Eduardo Oliveira Matos, Universidade Federal de Sergipe

Pharmacist (2016) from the Federal University of Sergipe (UFS). Resident in the Multiprofessional Postgraduate Program in Hospital Health Care (HUL-UFS/EBSERH).
Researcher at the Transdisciplinary Nucleus of Studies in Collective Health (NUTESC).

Izadora Menezes da Cunha Barros, Federal University of Sergipe

Pharmacist graduated from Tiradentes University (2010). Master in Pharmaceutical Sciences at the Federal University of Sergipe (2013). Doctor by the Postgraduate Program in Health Sciences (2016). She is currently an Adjunct Professor at the Federal University of Sergipe - UFS, at the Department of Pharmacy -DFAL of the Antônio Garcia Filho Campus (Lagarto-SE). Member of the Laboratory of Studies in Pharmaceutical Care (LECFAR) and of the Teaching and Research Group in Social Pharmacy (GEPFS). Professor of Pharmaceutical Teaching Practices in the Community and the Professional Master's Program in Management and Technological Innovation in Health (PPGITS). Develops research in the areas of Clinical Pharmacy, Pharmaceutical Assistance and Pharmaceutical Communication. Exercises tutoring activity in the Multiprofessional Residency of Hospital Care.

Júlia Santana Lisboa, Federal University of Sergipe

Graduated in Pharmacy at the Federal University of Sergipe, postgraduate in Pharmaceutical Care and Clinical Pharmacy at IPOG, and also in Hospital Pharmacy. Internship at HUSE and Health Care Center in Sergipe, for 6 months each. I am a specialist in Hospital Health Care - Lagarto (HUL). I worked as a pharmacist at the Sergipe Health Care Center for 9 months, and for 5 months at the Health Promotion and Assistance Institute (IPES). I have experience in the hospital area, in extensive actions, participation in several practical courses, including the course on injectables, held at UFS; complete computer course and willing to new experiences.

Samara Siqueira Santos Fernandes, Universitary Hospital of Lagarto

Graduated in Pharmacy from the Federal University of Sergipe (2009), specialization in Public Health Management from FACEAR & MASTERIDÉIA (2013) and specialization in Health Education for SUS Preceptors from the Instituto Sírio Libanês de Ensino e Pesquisa (2013). Worked in the clinical analysis area at Clínica Vitae LTDA. (2010 - 2014), being technically responsible for the clinical analysis laboratory and responsible for the implementation of the Quality Management System (PNCQ - Manager) of the same. She is currently a pharmacist at Hospital Regional Dr. Pedro Garcia Moreno Filho and Hospital Universitário de Lagarto, working in the area of ​​hospital pharmacy and pharmaceutical assistance.

Thaisa Calumby Lima, Universitary Hospital of Lagarto

Industrial Clinical Pharmacist from the Federal University of Sergipe - UFS.
Post-graduated in Hospital Pharmacy from the International University Center (UNINTER).
Pharmacist at the University Hospital of Lagarto, Sergipe, working in the area of ​​logistics and supply, dispensing and clinical pharmacy.

References

Barkun, A. N., Bardou, M., Pham, C. Q. D., & Martel, M. (2012). Proton Pump Inhibitors vs. Histamine 2 Receptor Antagonists for Stress-Related Mucosal Bleeding Prophylaxis in Critically Ill Patients: A Meta-Analysis. The American Journal Of Gastroenterology. 107(4) 507- 520. http://dx.doi.org/10.1038/ajg.2011.474.

Barreto, M. L. & Filho, N. A. (2011). Epidemiologia & Saúde: Fundamentos, Métodos e Aplicações – parte 2. Koogan

Cunha, N., & Machado, A. P. (2018). Proton pump inhibitors and the risk of severe adverse events - A cardiovascular bombshell?. Rev Port Cardiol. 37(10). 10.1016/j.repc.2017.10.012.

Damascena, R. S., & Costa, M. P. (2020). Perfil de Usuários de Omeprazol e Considerações Sobre Seu Uso Racional: Uma Revisão Bibliográfica. Id on Line Rev. Mult. Psic. 14(50). 10.14295/idonline.v14i50.2523.

Farrell, B., Pottie, K., Thompson, W., Boghossian, T., Pizzola, L., Rashid, F. J., Rojas-Fernandez, C., Walsh, K., Welch, V., & Moayyedi, P. (2017). Deprescribing proton pump inhibitors. Evidence-based clinical practice guideline. Canadian Family Physician May. 63(5). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5429051/.

Fioramonte, G. S., Brito, G. D., & Marques, G. L. (2020). Qualidade das prescrições de profilaxia para lesão aguda de mucosa gástrica em um hospital universitário no Brasil. Rev Med. 99(2). http://dx.doi.org/10.11606/issn.1679-9836.v99i2p122-127.

Forgacs, I., & Loganayagam, A. (2008). Overprescribing proton pump inhibitors. BMJ. 336(7634). 10.1136/bmj.39406.449456.BE.

Heidelbaugh, J. J., Goldberg, K. L., Inadomi, J. M. (2010). Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. Am J Manag Care. 16(9). https://pubmed.ncbi.nlm.nih.gov/21250399/.

Heidelbaugh, J. J., & Inadomi, J. M. (2006). Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients. Am J Gastroenterol. 101(10). 10.1111/j.1572-0241.2006.00839.x.

Klatte, D. C. F., Gasparini, A., Xu, H., Deco, P., Trevisan, M., Johansson, A. L. V., Wettermark, B., Ärnlöv, J., Cynthia, J. J., Bengt, L., Friedo, W. D., Josef, C., Morgan, E. G., & Juan, J. C. (2017). Association Between Proton Pump Inhibitor Use and Risk of Progression of Chronic Kidney Disease. Gastroenterology. 153(3). https://doi.org/10.1053/j.gastro.2017.05.046.

Lamont, J. T., Bakken, J. S., & Kelly, C. P. (2021). Clostridioides (formerly Clostridium) difficile infection in adults: Epidemiology, microbiology, and pathophysiology. UpToDate.

Li, W., Yu, L., & Zhou, Q. (2013). Pharmacokinetic drug interaction profile of omeprazole with adverse consequencesand clinical risk management. Ther Clin Risk Manag. 10.2147/TCRM.S43151.

Malfertheiner, P., Kandulski, A., & Venerito, M. (2017). Proton-pump inhibitors: understanding the complications and risks. Nat Rev Gastroenterol Hepatol. 10.1038/nrgastro.2017.117.

Peng, Y. C., Lin, C. L., Yeh, H. Z., Chang, C. S., Wu, Y. L., Kao, C. H. (2016). Association Between the Use of Proton Pump Inhibitors and the Risk of ESRD in Renal Diseases: A Population-Based, Case-Control Study. Medicine (Baltimore). 95(15). 10.1097/MD.0000000000003363.

Raseen, T., Singh, S., Gupta, A., Pardi, D. S., & Khanna, S. (2017). Association of Gastric Acid Suppression With Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis. JAMA Intern Med. 177(6). DOI:10.1001/jamainternmed.2017.0212.

Reimer, C. (2013). Safety of long-term PPI therapy. Best Practice & Research Clinical Gastroenterology. 27(3). 10.1016/j.bpg.2013.06.001.

Romanowski, F.F.A et al (2019). Manual de tipos de estudo. Produção técnica de pós-graduação em odontologia. Centro Universtiário de Anápolis). Anápolis, Goiás.

Stetler, B. C., Morsi, D., Rucki, S., Broughton, S., Corrigan, B., Fitzgerald, J., Giuliano, K., Havener, P., & Sheridan, E. A. (1998). Utilization-focused integrative reviews in a nursing service. Appls Nurs Res. 11(4). 10.1016/s0897-1897(98)80329-7.

Toews, I., George, A. T., Peter, J. V., Kirubakaran, R., Fontes, L. E. S., Ezekiel, J. P. B., Meerpohl, J. J. (2018). Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units. Cochrane Database Syst Rev. 6(6). 10.1002/14651858.CD008687.pub2.

Tomlinson, L. A., Fogarty, D. G., Douglas, I., & Nitsch, D. (2017). Pharmacoepidemiology for nephrologists: do proton pump inhibitors cause chronic kidney disease?. Nephrol Dial Transplant. 1(32). 10.1093/ndt/gfw349.

Weinhouse, G. L. (2022). Stress ulcers in the intensive care unit: Diagnosis, management and prevention. UpToDate.

Wolfe, M. (2021). Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders. UpToDate.

World Health Organization - Who. (2015). Model List of Essential Medicines. WHO technical Report Series, Geneve.

Downloads

Published

18/06/2022

How to Cite

CARDOSO, D. S. .; MATOS, L. E. O.; BARROS, I. M. da C.; LISBOA, J. S.; FERNANDES, S. S. S.; LIMA, T. C. Development of a proton pump inhibitor protocol in the prophylaxis of acute gastric mucosal injury: experience report. Research, Society and Development, [S. l.], v. 11, n. 8, p. e25211830865, 2022. DOI: 10.33448/rsd-v11i8.30865. Disponível em: https://www.rsdjournal.org/index.php/rsd/article/view/30865. Acesso em: 25 apr. 2024.

Issue

Vol. 11 No. 8

Section

Health Sciences

License

Copyright (c) 2022 Damaris Santana Cardoso; Luiz Eduardo Oliveira Matos; Izadora Menezes da Cunha Barros; Júlia Santana Lisboa; Samara Siqueira Santos Fernandes; Thaisa Calumby Lima

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.